| Securities | Issuer | Type | Symbol / Root |
| iShares NASDAQ Biotechnology Index Fund Fund | NASDAQ | iShares | IBB |
| NASDAQ Biotechnology | Chicago Mercantile Exchange | Futures | |
| The NASDAQ Biotechnology Index Option | American Stock Exchange | Options |
The iShares NASDAQ Biotechnology Index Fund seeks investment results that correspond generally to the price and yield performance, before fees and expenses, of companies primarily engaged in the biotechnology industry, as represented by the NASDAQ Biotechnology Index.
The NASDAQ Biotechnology Index contains securities of NASDAQ-listed companies classified as either Biotechnology or Pharmaceuticals and is calculated under a modified capitalization-weighted methodology.
Initially traded on the AMEX, On September. 23, 2008 The NASDAQ OMX Group, Inc. began trading the iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB) on The NASDAQ Stock Market. Barclays Global Investors (BGI), one of the world's largest institutional asset managers and Exchange Traded Funds (ETF) managers, transferred the funds to NASDAQ from the American Stock Exchange.
NASDAQ Biotechnology futures are designed to track the price movements of the NASDAQ Biotechnology Index and provide a tool for trading the biotechnology market sector.
The new NASDAQ Biotechnology Index futures contracts were launched in 2005, and are traded exclusively on the CME. The NASDAQ Biotechnology contracts are designed to hedge risks in the biotechnology sector.